Cargando…
Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis
BACKGROUND: Orally administered fluralaner (13.64% w/w) is effective for treating canine generalized demodicosis. A study was initiated to assess the efficacy of a novel 5.46% w/w fluralaner chewable tablet formulation for monthly administration in the treatment of this disease. METHODS: Client-owne...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917636/ https://www.ncbi.nlm.nih.gov/pubmed/35279216 http://dx.doi.org/10.1186/s13071-022-05213-x |
_version_ | 1784668591309717504 |
---|---|
author | Rohdich, Nadja Meyer, Leon Guerino, Frank |
author_facet | Rohdich, Nadja Meyer, Leon Guerino, Frank |
author_sort | Rohdich, Nadja |
collection | PubMed |
description | BACKGROUND: Orally administered fluralaner (13.64% w/w) is effective for treating canine generalized demodicosis. A study was initiated to assess the efficacy of a novel 5.46% w/w fluralaner chewable tablet formulation for monthly administration in the treatment of this disease. METHODS: Client-owned dogs diagnosed with generalized demodicosis were acclimatized to laboratory conditions and randomized to receive either orally administered fluralaner (Bravecto(®) 1-Month) (10.0 to 14.4 mg/kg body weight) (n = 8) or topical imidacloprid-moxidectin (Advocate(®) for dogs, Elanco) applied per label on days 0, 28, and 56 (n = 8), or more frequently for ongoing severe demodicosis. On days −2, 28, 56, and 84, deep skin scrapings were taken from five sites on each dog for mite identification and counting, and semiquantitative clinical assessments of generalized demodicosis were recorded. Primary efficacy was based upon arithmetic mean mite count reductions relative to pre-treatment. RESULTS: By day 28, mean pre-treatment mite counts, > 600 in both groups, were significantly reduced by 99.7% and 89.5% (both P < 0.001) in the fluralaner and imidacloprid-moxidectin groups, respectively. Parasitological cure (100% reduction in mite counts on days 56 and 84) was achieved in all fluralaner-treated dogs (100%) and in two imidacloprid-moxidectin-treated dogs (25%). In the imidacloprid-moxidectin group, the reduction in mean mite counts was 89.5% (day 28), 94.4% (day 56), and 97.5% (day 84). All study dogs were free of crusts on days 56 and 84. Scales resolved by day 84 in all fluralaner-treated dogs and in three imidacloprid-moxidectin-treated dogs. All fluralaner-treated dogs and five imidacloprid-moxidectin-treated dogs had > 90% hair regrowth on day 84. CONCLUSION: Three consecutive monthly orally administered treatments with fluralaner (5.46% w/w) flavored chewable tablets (minimum dose rate 10 mg/kg body weight) eliminated Demodex canis mites from dogs diagnosed with generalized demodicosis. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-8917636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89176362022-03-21 Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis Rohdich, Nadja Meyer, Leon Guerino, Frank Parasit Vectors Research BACKGROUND: Orally administered fluralaner (13.64% w/w) is effective for treating canine generalized demodicosis. A study was initiated to assess the efficacy of a novel 5.46% w/w fluralaner chewable tablet formulation for monthly administration in the treatment of this disease. METHODS: Client-owned dogs diagnosed with generalized demodicosis were acclimatized to laboratory conditions and randomized to receive either orally administered fluralaner (Bravecto(®) 1-Month) (10.0 to 14.4 mg/kg body weight) (n = 8) or topical imidacloprid-moxidectin (Advocate(®) for dogs, Elanco) applied per label on days 0, 28, and 56 (n = 8), or more frequently for ongoing severe demodicosis. On days −2, 28, 56, and 84, deep skin scrapings were taken from five sites on each dog for mite identification and counting, and semiquantitative clinical assessments of generalized demodicosis were recorded. Primary efficacy was based upon arithmetic mean mite count reductions relative to pre-treatment. RESULTS: By day 28, mean pre-treatment mite counts, > 600 in both groups, were significantly reduced by 99.7% and 89.5% (both P < 0.001) in the fluralaner and imidacloprid-moxidectin groups, respectively. Parasitological cure (100% reduction in mite counts on days 56 and 84) was achieved in all fluralaner-treated dogs (100%) and in two imidacloprid-moxidectin-treated dogs (25%). In the imidacloprid-moxidectin group, the reduction in mean mite counts was 89.5% (day 28), 94.4% (day 56), and 97.5% (day 84). All study dogs were free of crusts on days 56 and 84. Scales resolved by day 84 in all fluralaner-treated dogs and in three imidacloprid-moxidectin-treated dogs. All fluralaner-treated dogs and five imidacloprid-moxidectin-treated dogs had > 90% hair regrowth on day 84. CONCLUSION: Three consecutive monthly orally administered treatments with fluralaner (5.46% w/w) flavored chewable tablets (minimum dose rate 10 mg/kg body weight) eliminated Demodex canis mites from dogs diagnosed with generalized demodicosis. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2022-03-12 /pmc/articles/PMC8917636/ /pubmed/35279216 http://dx.doi.org/10.1186/s13071-022-05213-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rohdich, Nadja Meyer, Leon Guerino, Frank Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis |
title | Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis |
title_full | Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis |
title_fullStr | Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis |
title_full_unstemmed | Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis |
title_short | Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis |
title_sort | fluralaner 5.46% (w/w) flavored chewable tablet (bravecto(®) 1-month) is effective for treatment of canine generalized demodicosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917636/ https://www.ncbi.nlm.nih.gov/pubmed/35279216 http://dx.doi.org/10.1186/s13071-022-05213-x |
work_keys_str_mv | AT rohdichnadja fluralaner546wwflavoredchewabletabletbravecto1monthiseffectivefortreatmentofcaninegeneralizeddemodicosis AT meyerleon fluralaner546wwflavoredchewabletabletbravecto1monthiseffectivefortreatmentofcaninegeneralizeddemodicosis AT guerinofrank fluralaner546wwflavoredchewabletabletbravecto1monthiseffectivefortreatmentofcaninegeneralizeddemodicosis |